CLAIMS

1. A process for spray drying of a feed solution comprising semaglutide, said process comprising introducing the feed solution comprising semaglutide in a solvent into a spray dryer and introducing an atomising gas and a drying gas, characterised in that the spray dryer comprises a gas heater for the drying gas with an inner surface comprising iron and ~~less than 18.5%~~ 10-18.5% chromium.

2. The process according to claim 1, characterised in that the inner surface comprises 14-18.5% chromium.

~~2.~~3. The process according to claim 1, characterised in that the inner surface comprises 16-18% chromium.

~~3.~~4. The process according to any of the preceding claims, characterised in that the inner surface comprises 10-14% nickel.

~~4.~~5. The process according to any of the preceding claims, characterised in that the inner surface comprises 16-18% chromium and 10-14% nickel.

~~5.~~6. The process according to any one of the preceding claims, characterised in that the inner surface has a depth of 0.001 cm to 10 cm.

~~6.~~7. The process according to any one of the preceding claims, characterised in that the feed solution solvent comprises ethanol.

~~7.~~8. The process according to any one of the preceding claims, characterised in that the feed solution comprises 0.5-2.5% (w/w) semaglutide in 49-60% (w/w) aqueous ethanol.

~~8.~~9. The process according to any one of the preceding claims, characterised in that the drying gas is nitrogen.

~~9.~~10. The process according to any one of the preceding claims, characterised in that the drying gas is recirculated.

11. A process for spray drying of a feed solution comprising semaglutide, said process comprising introducing the feed solution comprising semaglutide in a solvent into a spray dryer and introducing an atomising gas and a drying gas, characterised in that the spray dryer comprises a gas heater for the drying gas with an inner surface comprising iron, 16-18% chromium and 10-14% nickel, wherein the feed solution comprising 0.5-2.5% (w/w) semaglutide in 49-60% (w/w) aqueous ethanol.

~~10.~~12. The process according to any one of the preceding claims further comprising a step of formulating semaglutide obtained by said process into a pharmaceutical composition.

~~11.~~13. The process according to claim ~~10~~ 12, wherein said pharmaceutical composition is a tablet.

~~12. The product obtainable by the process according to any one of claims 1-11, characterised by comprising less than 0.3% impurities~~

~~13. The pharmaceutical composition according to claim 10, the tablet according to claim 11 or the product according to claim 12 for use in medicine.~~

~~14. The pharmaceutical composition according to claim 10, the tablet according to claim 11 or the product according to claim 12 for use in the prevention and/or treatment of obesity and/or diabetes.~~

~~15. The pharmaceutical composition according to claim 10, the tablet according to claim 11 or the product according to claim 12 for use in the prevention and/or treatment of overweight, obesity, hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes and/or NASH.~~